Sanofi shares rise 8.80% after-hours after completing acquisition of Vigil Neuroscience.

Sanofi rose 8.80% in after-hours trading, with the company completing the acquisition of Vigil Neuroscience, Inc. This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer’s disease. Additionally, the acquisition of Vigil’s preclinical pipeline will further strengthen Sanofi’s research in various neurodegenerative diseases.